MYN
Mainz Biomed
Stock
Stock
ISIN: NL0015000LC2
Ticker: MYNZ
NL0015000LC2
MYNZ
Price
Price
CHART BY
Frequently asked questions
What is Mainz Biomed's market capitalization?
The market capitalization of Mainz Biomed is $7.48M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Mainz Biomed?
Mainz Biomed's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$65.57. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Mainz Biomed's stock?
Currently, 1 analysts cover Mainz Biomed's stock, with a consensus target price of $14.00. Analyst ratings provide insights into the stock's expected performance.
What is Mainz Biomed's revenue over the trailing twelve months?
Over the trailing twelve months, Mainz Biomed reported a revenue of $895.48K.
What is the EBITDA for Mainz Biomed?
Mainz Biomed's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$25.48M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Mainz Biomed?
Mainz Biomed has a free cash flow of -$23.14M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Mainz Biomed have, and what sector and industry does it belong to?
Mainz Biomed employs approximately 26 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Mainz Biomed's shares?
The free float of Mainz Biomed is 3.69M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $7.48M
- EPS (TTM)
- -$65.57
- Free Float
- 3.69M
- Revenue (TTM)
- $895.48K
- EBITDA (TTM)
- -$25.48M
- Free Cashflow (TTM)
- -$23.14M
Pricing
- 52W span
- $1.34$18.80
Analyst Ratings
The price target is $14.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.
- Employees
- 26
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- NL0015000LC2
- Primary Ticker
- MYNZ
Fundamentals & EOD data from FactSet